Keybanc Maintains Overweight on La-Z-Boy, Lowers Price Target to $40
Keybanc analyst Bradley B. Thomas maintains La-Z-Boy (NYSE:LZB) with a Overweight and lowers the price target from $46 to $40.
Read original at benzingaStocks · News reference
La-Z-Boy Sees Q2 Sales $500.000M-$520.000M vs $536.792M Est
La-Z-Boy (NYSE:LZB) sees Q2 sales of $500.000 million-$520.000 million vs $536.792 million analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 8:16 PM
- Checked
- Aug 18, 2026, 8:16 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
La-Z-Boy Q1 2027 Earnings Call: Complete Transcript
La-Z-Boy (NYSE:LZB) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our
Read original at benzingaLa-Z-Boy shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 sales guidance below estimates.
Read original at benzingaMarket-Moving News for August 19th
TNON: 110% | Tenon Medical shares are trading higher after the company received a notice of allowance for a U.S. Patent Titled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints" LZB: -18% |
Read original at benzinga